©The Author(s) 2019.
World J Gastroenterol. Apr 7, 2019; 25(13): 1603-1617
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1603
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1603
Table 4 Documented suspected side effects of tacrolimus during intravenous and oral treatment
| Suspected side effect | n = 22 |
| None, n (%) | 10/22 (45.5) |
| Treatment discontinuation due to side effects, n (%) | 2/22 (9.1) (1 due to severe vomiting, 1 due to anemia and leukopenia) |
| Nausea ± vomiting, n (%) | 3/22 (13.6) |
| Stomach pain, n (%) | 1/22 (4.5) |
| Headache, n (%) | 1/22 (4.5) |
| Tremor, n (%) | 4/22 (18.2) |
| Paresthesias, n (%) | 1/22 (4.5) |
| Photosensitivity, n (%) | 1/22 (4.5) |
| Itching rash, n (%) | 1/22 (4.5) |
| Joint or back pain, n (%) | 1/22 (4.5) |
| Muscle pain or cramps, n (%) | 2/22 (9.1) |
| Temperature intolerance, n (%) | 3/22 (13.6) |
| Anemia, leukopenia, n (%) | 1/22 (4.5) |
| Loss of hair, n (%) | 1/22 (4.5) |
- Citation: Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 2019; 25(13): 1603-1617
- URL: https://www.wjgnet.com/1007-9327/full/v25/i13/1603.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i13.1603